Drugs / ATH3G10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03991143 | Mar 2019 → Jul 2020 | ST-elevation myocardial infarction | Athera Biotechnologies AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATH3G10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03991143 ↗ |
| Modality | Monoclonal antibody | “the Monoclonal Antibody ATH3G10” NCT03991143 ↗ |